AstraZeneca’s Imfinzi shows benefits in endometrial cancer trial
UK-based pharmaceutical company AstraZeneca has reported treatment benefits in findings from the DUO-E Phase III clinical trial of Imfinzi (durvalumab) plus Lynparza (olaparib).…
UK-based pharmaceutical company AstraZeneca has reported treatment benefits in findings from the DUO-E Phase III clinical trial of Imfinzi (durvalumab) plus Lynparza (olaparib).…
Chinese biotechnology company Innovent Biologics has reported that the Phase II clinical trial of efdamrofusp alfa high-dose (IBI302) in Chinese…
Lantern Pharma has dosed two subjects in a Phase Ia/Ib clinical trial of its investigational drug LP-284 for relapsed or…
GSK has announced promising results from the Phase III RUBY/ENGOT-EN6/GOG3031/NSGO clinical trial of the programmed death receptor-1 (PD-1)-hindering antibody Jemperli…
Merck (MSD) has reported that the Phase III KEYNOTE-A18 (ENGOT-cx11/GOG-3047) clinical trial of Keytruda plus chemoradiotherapy (CRT) in cervical cancer…
Nuvation Bio has dosed the first subject in a Phase I/II clinical trial of NUV-1511, a new drug-drug conjugate (DDC)…
Recce Pharmaceuticals has announced the conclusion of subject dosing in the latest cohort of its Phase I/II clinical trial of…
OcuTerra Therapeutics has reported that its Phase II DR:EAM clinical trial of selective RGD integrin inhibitor nesvategrast (OTT166) eye drops…
Nuvectis Pharma has released preliminary findings from the ongoing Phase Ib clinical trial of NXP800, aimed at treating patients with…
NeuroBo Pharmaceuticals has received approval from the Safety Review Committee (SRC) to proceed with its Phase IIa clinical trial of…